• Alias: BAY94-9343
    • Fully human IgG1 monoclonal antibody against the cell surface glycoprotein mesothelin
    • Mesothelin is selectively overexpressed in many human tumors (e.g., pancreas 80%–100%, ovary 80%, mesothelioma 100%, and lung 40%).
    • The mAb moiety of antimesothelin antibody–drug conjugate BAY 94-9343 targets and binds to the TAA mesothelin; when internalized, the DM4 moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of mesothelin-expressing tumor cells.
    • Currently in phase 1 clinical development
    • Potential cancer targets: Mesothelioma, ovarian cancer, pancreatic cancer, NSCLC
    • Starting dose: 5.5 once a week and continue to escalate
    Other topics in Targeted and Immunotherapy Agents